Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals
1995 FOUNDED
PUBLIC STATUS
201-300 EMPLOYEES
LXRX STOCK SYMBOL
3 INVESTMENTS
$2.94 SHARE PRICE (As of Tuesday Closing)
Description

Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.

Formerly Known As
Lexicon Genetics
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Primary Office
  • 8800 Technology Forest Place
  • The Woodlands, TX 77381
  • United States

+1 (281) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Lexicon Pharmaceuticals’s full profile, request a free trial.

Lexicon Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.12 - $11.51 $312M $2.74 -$0.84 1.81M 106M

Lexicon Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 780,332 760,993 946,535 1,145,097
Revenue 43,147 63,209 91,689 79,256
EBITDA (67,257) (99,596) (127,225) (125,115)
Net Income (88,582) (120,548) (122,993) (131,445)
Total Assets 233,143 284,136 436,539 475,625
Total Debt 245,068 245,002 245,670 101,447
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lexicon Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Lexicon Pharmaceuticals Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regulus Therapeutics Corporation San Diego, CA 00 00000 000000000 00000
000000000(00000000 Formerly VC-backed New York, NY 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 00000000 00.000
000000000000 00000 Corporate Backed or Acquired Trevose, PA 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Lexicon Pharmaceuticals Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 02-Aug-2010 000000000000000000 0000 Pharmaceuticals 000000 00000 00.0
00000000 0000 01-Jun-2007 00000 0000000 Pharmaceuticals 000000 00000 00.0
Coelacanth Chemical 12-Jul-2001 Merger/Acquisition 0000 Pharmaceuticals 000000 00000 00.0
To view this company’s complete investment and acquisition history, request access »

Lexicon Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Lexicon Pharmaceuticals Executive Team (11)

Name Title Board
Seat
Contact
Info
Lonnel Coats Chief Executive Officer & Board Member
Jeffrey Wade JD Chief Financial Officer & Executive Vice President
James Tessmer Chief Accounting Officer & Vice President
Pablo Lapuerta MD Chief Medical Officer & Executive Vice President
Alan Main Ph.D Executive Vice President

5 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

Lexicon Pharmaceuticals Board Members (9)

Name Representing Role Since Contact
Info
0000 0000 00 Self Board Member 000 0000
00000000000 0000000 The Invus Group Board Member 000 0000
00000 000000000 Self Board Member 000 0000
000000 00000 Self Board Member 000 0000
000000 00000 Lexicon Pharmaceuticals Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »